News + Publications

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced the presentation of new preclinical data supporting its SEND (Synthetic Efficacy eNableD) T cell armoring strategy at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11–15, 2026 in Boston. The data will be presented in a poster entitled, “SEND – A T cell armoring strategy that incorporates simultaneous signaling through multiple pathways for optimized safety and efficacy via novel cell state,” during a poster session on Thursday, May 14, from 5:00 – 6:30 p.m.